close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pyxis Oncology, Inc. - Common Stock (NQ:PYXS)

1.450 +0.080 (+5.84%)
Streaming Delayed Price Updated: 2:34 PM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pyxis Oncology, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology Announces $50 Million Private Placement
From Pyxis Oncology
Via GlobeNewswire
News headline image
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings. 
Via Benzinga
News headline image
3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024 ↗
With new innovation and high demand, biotech stocks could offer some of the most explosive opportunities of the year. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer
Dr. Kobayashi brings over 25 years of experience in oncology drug development, including Antibody Drug Conjugates (ADCs) and other oncology modalities 
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update
From Pyxis Oncology
Via GlobeNewswire
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:PYXS),(NASDAQ:AZN),(NYSE:LLY),(NASDAQ:MRUS) EQNX::TICKER_END 
Via FinancialNewsMedia
NASDAQ:PYXS Investor Notice: Investigation over Possible Securities Laws Violations by Pyxis Oncology, Inc. ↗
San Diego, CA -- (SBWIRE) -- 10/05/2023 -- Pyxis Oncology, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
News headline image
Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology M&A Spotlight Signals Potential Growth Amidst Competitive ADC Landscape: Analyst ↗
RBC Capital Markets has initiated coverage on Pyxis Oncology Inc (NASDAQ: PYXS) with an Outperform rating and a  
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 5, 2023 ↗
 
Via Benzinga
News headline image
Pyxis Oncology to Participate in Two Upcoming Investment Conferences
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology Successfully Completes Acquisition of Apexigen
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology Reports Financial Results for Second-Quarter 2023 and Provides Corporate Update
From Pyxis Oncology
Via GlobeNewswire
News headline image
Pyxis Oncology to Present at BTIG Virtual Biotechnology Conference
From Pyxis Oncology
Via GlobeNewswire
News headline image
Small SPAC Biotech Apexigen To Be Acquired Pyxis Oncology For $16M ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023 ↗
 
Via Benzinga
News headline image
Pyxis Oncology Bolsters Oncology Portfolio Through $16M Apexigen Acquisition ↗
Pyxis Oncology (NASDAQ:PYXS) has announced an acquisition of Apexigen (NASDAQ:APGN) that is expected to be completed in the second half of 2023. 
Via Benzinga
News headline image
Why Is Apexigen (APGN) Stock Up 31% Today? ↗
Apexigen (APGN) stock is rising higher on Wednesday following news of a $16 million acquisition deal with Pyxis Oncology (PYXS). 
Via InvestorPlace
News headline image
Why Chicken Soup For The Soul Entertainment Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket ↗
Gainers RiceBran Technologies (NASDAQ: RIBT) gained 43.1% to $1.33 in pre-market trading after gaining 3% on Tuesday. 
Via Benzinga
News headline image
Why Bullfrog AI Holdings Shares Are Trading Higher By 73%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Secoo Holding Limited (NASDAQ: SECO) shares surged 138% to $1.43. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Y-mAbs Therapeutics Shares Are Trading Higher By 50%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Gainers Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) climbed 49.9% to $4.93 after the company posted a profit for the fourth quarter. 
Via Benzinga
News headline image
Top 5 Health Care Stocks That May Collapse ↗
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today